The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family. Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is known to trigger tumor cell growth, survival, invasion, metastasis, angiogenesis, epithelial to mesenchymal transition, and i...

Full description

Bibliographic Details
Main Authors: Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sun Min Lim
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
AXL
AXL inhibitor
resistance
targeted therapy
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.811247/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.811247/full

Similar Items